BEVAREST 400MG

Bevarest-400 Injection is a monoclonal antibody utilized in the treatment of metastatic breast cancer, non-small cell lung cancer, kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cancers of the colon and rectum. Cancer is characterized by the uncontrolled growth and reproduction of cells in a specific area of the body. It can originate in one location and spread to other regions, a process known as metastasis.

The active ingredient in Bevarest-400 Injection is ‘Bevacizumab’, which targets vascular endothelial growth factor (VEGF) present on the lining of lymphatic and blood vessels. VEGF promotes the growth of blood vessels within tumors, supplying them with oxygen and nutrients. By inhibiting vascular endothelial growth factor, the flow of oxygen and nutrients to the tumor is restricted, leading to its reduction or halting its growth. Consequently, this aids in the treatment of various cancers.

Bevarest-400 Injection will be administered by a qualified healthcare professional; self-administration is not permitted. Your doctor will determine the appropriate dosage and duration based on your medical condition. In certain instances, Bevarest-400 Injection may result in side effects such as loss of appetite, constipation, fever, nosebleeds, alterations in speech, and changes in taste. Most of these side effects are manageable and will resolve over time. However, if the side effects persist or worsen, it is important to consult your physician.

Avoid using Bevarest-400 Injection if you are pregnant. It is essential to employ effective contraception during treatment and for six months following the final dose. Bevarest-400 Injection may induce drowsiness and fainting; therefore, refrain from driving while undergoing treatment. Additionally, do not breastfeed during the treatment period and for six months after the last dose of Bevarest-400 Injection. Keep your healthcare provider updated about your health status.